spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  C1 inhibitor 

 HSMN NewsFeed - 17 Jan 2018
Pharming Announces FDA Acceptance for Review of Supplemental Biologics License Application for RUCONEST(R) for Prophylaxis of Hereditary Angioedema Attacks
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Nov 2017
Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST(R) for Prophylaxis of Hereditary Angioedema Attacks
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Mar 2017
Shire Receives European Approval for Label Extension of CINRYZE(R) (C1 inhibitor ) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Dec 2015
Navitor Pharmaceuticals Announces $33 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Nov 2014
Salix and Pharming Announce the Launch of RUCONEST(R) in the U.S. for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 17 Jul 2014
Salix and Pharming Announce FDA Approval of RUCONEST(R) for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Nov 2013
Shire to Acquire ViroPharma in Strategic Move to Strengthen Rare Disease Portfolio; Will Augment Already Strong Growth Prospects
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Apr 2012
Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Feb 2012
Santarus Announces FDA Acceptance of UCERIS New Drug Application for Induction of Remission of Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 13 Feb 2012
Santarus Announces Initiation of Phase IIIb Study with UCERIS in Patients with Mild or Moderate Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 6 Feb 2012
Santarus Begins Promoting Cholesterol-Lowering Product FENOGLIDE
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2011
Santarus and Pharming Announce Receipt of FDA Refusal to File Letter for RHUCIN Biologics License Application
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Feb 2011
Santarus and Pharming Announce Initiation of Phase IIIb Clinical Study with RHUCIN in Acute Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 28 Dec 2010
Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
Biopharmaceuticals
 HSMN NewsFeed - 28 Dec 2010
Pharming and Swedish Orphan Biovitrum announce first sales of Ruconest in Europe
Biopharmaceuticals
 HSMN NewsFeed - 15 Nov 2010
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 5 Oct 2010
RHUCIN Clinical Trial Data Published in the Journal of Allergy and Clinical Immunology
Biopharmaceuticals
 HSMN NewsFeed - 13 Sep 2010
Pharming signs commercialization agreement with Santarus for Rhucin(R) in North America
Biopharmaceuticals
 HSMN NewsFeed - 11 Jan 2010
ViroPharma Expands Global Licensing, Commercialization and Development Rights for Cinryze(TM) (C1 esterase inhibitor [human])
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Jun 2009
ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Feb 2009
ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
Biopharmaceuticals
 HSMN NewsFeed - 9 Feb 2009
ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
Biopharmaceuticals
 HSMN NewsFeed - 3 Feb 2009
FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Oct 2008
ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 15 Jul 2008
ViroPharma To Acquire Lev Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 May 2008
Lev Pharmaceuticals Announces Cinryze(TM) Complete Response Submission Accepted for Review by FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 May 2008
Lev Announces FDA Advisory Committee Unanimously Recommends Approval of Cinryze(TM) for Hereditary Angioedema
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Apr 2008
Lev Pharmaceuticals Announces Submission of Complete Response to FDA for Cinryze(TM) for Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 25 Mar 2008
Pharming signs distribution agreement for Rhucin(R) in Turkey
Biopharmaceuticals Distribution
 HSMN NewsFeed - 20 Mar 2008
Pharming to receive Negative Opinion on European Marketing Authorization Application for Rhucin(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Feb 2008
ACAAI Publishes New Supplement on Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 26 Nov 2007
CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 14 Nov 2007
Lev Pharmaceuticals Expands Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Sep 2007
Lev Pharmaceuticals Meets Primary Endpoint in Pivotal Phase III Prophylactic Trial for Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 30 Aug 2007
Pharming Presents Positive Results from European Phase III Trial of Rhucin(R)
Biopharmaceuticals
 HSMN NewsFeed - 31 Jul 2007
Lev Pharmaceuticals Submits Biologics License Application for Cinryze(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Mar 2007
Pharming Strengthens Organization for Commercial Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jan 2007
Pharming Receives European Orphan Drug Designation
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Nov 2006
Positive Final Results from EDEMA2 Trial with DX-88 for the Treatment of Hereditary Angioedema Presented at ACAAI Meeting
Biopharmaceuticals
 HSMN NewsFeed - 1 Nov 2006
Pharming Shareholders Appoint Bruno Giannetti as Member of the Board of Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Sep 2006
Pharming Appoints Bruno Giannetti as Chief Operations Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jul 2006
Pharming Submits Marketing Authorisation Application for Recombinant Human C1 Inhibitor in Europe
Biopharmaceuticals Regulatory
Return to NewsFeed  

 Additional items found! 6

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 6 additional stories matching:
C1 inhibitor
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.